Literature DB >> 7769906

Prospects for immunological control of schistosomiasis.

D W Dunne1, P Hagan, F G Abath.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7769906     DOI： 10.1016/s0140-6736(95)91041-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Human immune responses to Schistosoma mansoni vaccine candidate antigens.

Authors:  A Ribeiro de Jesus; I Araújo; O Bacellar; A Magalhães; E Pearce; D Harn; M Strand; E M Carvalho
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

2.  Gender-dependent specific immune response during chronic human Schistosomiasis haematobia.

Authors:  F Remoué; D To Van; A M Schacht; M Picquet; O Garraud; J Vercruysse; A Ly; A Capron; G Riveau
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

3.  Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis.

Authors:  Gilles Riveau; Dominique Deplanque; Franck Remoué; Anne-Marie Schacht; Hubert Vodougnon; Monique Capron; Michel Thiry; Joseph Martial; Christian Libersa; André Capron
Journal:  PLoS Negl Trop Dis       Date:  2012-07-03

Review 4.  Metazoan Parasite Vaccines: Present Status and Future Prospects.

Authors:  Christian Stutzer; Sabine A Richards; Mariette Ferreira; Samantha Baron; Christine Maritz-Olivier
Journal:  Front Cell Infect Microbiol       Date:  2018-03-13       Impact factor: 5.293

5.  Cytokine responses to the anti-schistosome vaccine candidate antigen glutathione-S-transferase vary with host age and are boosted by praziquantel treatment.

Authors:  Claire D Bourke; Norman Nausch; Nadine Rujeni; Laura J Appleby; François Trottein; Nicholas Midzi; Takafira Mduluza; Francisca Mutapi
Journal:  PLoS Negl Trop Dis       Date:  2014-05-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.